Physician profile
Alan Koletsky
NPI 1952359234
$18,927.67
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,950 · 2020: $3,808 · 2021: $6,715 · 2022: $3,571 · 2023: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.35 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,440.13 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,294.92 | 2019-2022 | |
| Astellas Pharma Global Development | $2,241.00 | 2021 | |
| Exelixis INC. | $2,084.49 | 2019-2023 | Cabometyx |
| Seagen INC. | $1,731.17 | 2022-2023 | Padcev, Adcetris |
| Aveo Pharmaceuticals, INC. | $1,136.82 | 2021-2023 | Fotivda |
| Janssen Biotech, INC. | $863.76 | 2019-2022 | |
| Sirtex Medical INC | $593.23 | 2022-2023 | Sir-Spheres Microspheres |
| Astrazeneca Pharmaceuticals LP | $333.84 | 2019-2023 | Tagrisso |
| Novartis Pharmaceuticals Corporation | $333.67 | 2019-2023 | |
| Astellas Pharma US INC | $293.54 | 2019-2023 | Xtandi, Padcev |
| Genentech USA, INC. | $292.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $273.98 | 2019-2023 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $254.12 | 2019-2023 | Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.74 | 2019-2020 |
Show all 41 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Koletsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.